Aspen Biopharma Labs Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 08-07-2024
- Paid Up Capital ₹ 6.00 Cr
as on 08-07-2024
- Company Age 16 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 12.00 Cr
as on 08-07-2024
- Revenue 111.93%
(FY 2020)
- Profit 110.71%
(FY 2020)
- Ebitda 537.35%
(FY 2020)
- Net Worth 5.79%
(FY 2020)
- Total Assets 20.63%
(FY 2020)
About Aspen Biopharma Labs
The Corporate was formerly known as Tatorg Synthesis Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 6.00 Cr.
The company currently has active open charges totaling ₹12.00 Cr.
Pavan Yedhula and Satyanarayana Gajjela serve as directors at the Company.
- CIN/LLPIN
U24233TG2008PTC059617
- Company No.
059617
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jun 2008
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aspen Biopharma Labs Private Limited offer?
Aspen Biopharma Labs Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Vitamin Powder API, API (Active Pharmaceutical Ingredients), Organic and Inorganic Solvents, Solvent Ether.
Who are the key members and board of directors at Aspen Biopharma Labs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pavan Yedhula  | Director | Current | |
| Satyanarayana Gajjela | Director | Current |
Financial Performance of Aspen Biopharma Labs.
Aspen Biopharma Labs Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 111.93% increase. The company also saw a substantial improvement in profitability, with a 110.71% increase in profit. The company's net worth moved up by a moderate rise of 5.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aspen Biopharma Labs?
In 2020, Aspen Biopharma Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 Jan 2018 | ₹10.50 Cr | Open |
Andhra Bank Creation Date: 25 Apr 2015 | ₹1.50 Cr | Open |
How Many Employees Work at Aspen Biopharma Labs?
Aspen Biopharma Labs has a workforce of 1 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aspen Biopharma Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aspen Biopharma Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
